The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

PRIORITY PRESS - NF Conference 2023: Children’s Tumor Foundation (CTF)

A new option for the inoperable: Insights into management of NF1-associated plexiform neurofibromas

In-person/virtual, Scottsdale, Arizona / June 24–27, 2023

Scottsdale – The NF Conference is the flagship annual meeting of the US-based Children’s Tumor Foundation. This June, more than 700 participants from around the world gathered at the Fairmont Scottsdale Princess in...

MEDICAL FRONTIERS - Annual Meeting of the American College of Rheumatology (ACR)

Management of Axial Disease in Patients with PsA and SpA Pandemic

Atlanta, Georgia / November 8-13, 2019

Atlanta – The spine was in the spotlight at the ACR meeting in Atlanta. Axial psoriatic arthritis (PsA) and axial spondyloarthitis (SpA) featured in more than 200 posters and sessions, including landmark studies in neglected areas....

MEDICAL FRONTIERS - 26th European Academy of Dermatology and Venereology Congress

A Long-Term Update with IL-17A Inhibition

Geneva, Switzerland / September 13-17, 2017

Geneva - Long-term data are emerging with the interleukin (IL)-17A inhibitors in the treatment of patients with moderate to severe plaque psoriasis and psoriatic arthritis. These findings, from open-label extensions of phase 2 and phase 3...

PRIORITY PRESS - 25th Congress of European Academy of Dermatology and Venerology (EADV)

Comorbidities in Psoriasis in the Dermatology Clinic: New Considerations

Vienna, Austria / September 28- October 2, 2016

Vienna - Over the past decade there has been growing recognition that psoriasis is more than just an isolated skin disease as it is has become associated with other disorders. A common trend featured throughout the conference was the...

PRIORITY PRESS - 8th World Congress of Melanoma

New Advances in the Treatment of Basal Cell Carcinoma: Targeting the Hedgehog Signaling Pathway

Hamburg, Germany / July 17-20, 2013

Hamburg - Until recently, treatment options for advanced basal cell carcinoma (BCC) were limited and suboptimal. Research into novel therapeutic targets identified mutations in the hedgehog signaling pathway as a possible cause of new...

PRIORITY PRESS - 21st Congress of the European Academy of Dermatology and Venereology (EADV)

Progress in Advanced Basal-cell Carcinoma: Exploring Hedgehog Pathway Inhibition

Prague, Czech Republic / September 27-30, 2012

Prague - Basal-cell carcinoma (BCC) is the most commonly diagnosed human cancer worldwide. Most BCCs are readily treated by surgery, but some lesions progress to an advanced state (locally advanced BCC) or spread to distant sites...

PRIORITY PRESS - American Academy of Dermatology (AAD) Summer Academy Meeting 2012

Progress in the Treatment of Nail Disorders

Boston, Massachusetts / August 15-19, 2012

Boston - The first treatments directed specifically at improving the mechanical properties of nail plates are reaching clinical practice. In data presented at the summer meeting of the AAD, these treatments appear to improve nail strength...

PRIORITY PRESS - 88th Canadian Paediatric Society Annual Conference

Update on Atopic Dermatitis, Cutaneous Infestations in Paediatrics: Focus on Novel Strategies for Improved Control

Québec City, Québec / June 15-18, 2011

Québec City - Patients with atopic dermatitis or eczema will respond best to treatment if they understand the nature of their condition, how and when to treat it, and what the best treatment is. Despite patients’ perceptions, side effects...

MEDICAL FRONTIERS - A report from recent peer-reviewed publications and medical conferences

New Overview of Biologic Therapy Risks in Psoriasis

May 2011

The ability of highly targeted biologic agents to halt psoriasis and other inflammatory processes, first achieved with tumour necrosis factor alpha (TNF-a) inhibitors, has been a revolutionary advance for intractable cases. In psoriasis,...

PAGE 1 OF 4   1 2 3 4